Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array

Matsuoka,Hisashi; Kondo,Kazuya; Takizawa,Hiromitsu; Fujino,Haruhiko; Sakamoto,Etsuko; Uchida,Junji; Uyama,Koh; Toba,Hiroaki; Kenzaki,Koichiro; Sakiyama,Shoji; Tangoku,Akira

doi:10.3892/ijo.2014.2754

Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array

Authors:
- Hisashi Matsuoka
- Kazuya Kondo
- Hiromitsu Takizawa
- Haruhiko Fujino
- Etsuko Sakamoto
- Junji Uchida
- Koh Uyama
- Hiroaki Toba
- Koichiro Kenzaki
- Shoji Sakiyama
- Akira Tangoku
View Affiliations

Affiliations: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8509, Japan, Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8509, Japan, Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan, Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan
Published online on: November 17, 2014 https://doi.org/10.3892/ijo.2014.2754
Pages: 569-577

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

S-1 is a newly developed dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine that exhibits high clinical efficacy against non-small cell lung cancers. To identify genes that may be associated with chemosensitivity to the antitumor drug S-1, we used a low density array representing 93 genes to analyze expression profiles in 4 orthotopically implanted lung cancers derived from human lung cancer cell lines (Lu99, Lu130, LC6 and A549). The tumor growth inhibition (TGI) rates of S-1 in orthotopically implanted tumors of the Lu99, Lu130, LC6 and A549 cell lines were 34.6, 37.5, 32.1 and 3.6%, respectively. The expression of the PRSS3, ABCC4, TXN, SHMT1 and CMPK genes was significantly promoted in the orthotopically implanted SCID mouse model of the 4 lung cancer cell lines by the administration of S-1, while the expression of the LMO7 and FOLH1 genes was significantly suppressed. The expression of the ABCC1, 2 and TST genes was negatively correlated with TGI. The expression of the TK1 and ERCC2 genes was positively correlated with TGI. The results of the present study suggest that the expression of the ABCC1, 2, TST, TK1 and ERCC2 genes is related to resistance to the antitumor drug S-1.

View Figures

View References

1	Zembutsu H, Ohnishi Y, Tsunoda T, et al: Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:518–527. 2002.PubMed/NCBI
2	Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:1139–1147. 2002.PubMed/NCBI
3	Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS and Kim NS: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 214:19–33. 2004. View Article : Google Scholar : PubMed/NCBI
4	Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer. 37:1681–1687. 2001. View Article : Google Scholar : PubMed/NCBI
5	Francia G, Cruz-Munoz W, Man S, Xu P and Kerbel RS: Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 11:135–141. 2011. View Article : Google Scholar : PubMed/NCBI
6	Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 133:571–573. 1889. View Article : Google Scholar
7	Tashiro T, Inaba M, Kobayashi T, et al: Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol. 24:187–192. 1989. View Article : Google Scholar : PubMed/NCBI
8	Takechi T, Okabe H, Ikeda K, et al: Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep. 14:33–39. 2005.PubMed/NCBI
9	Ishikura H, Kondo K, Miyoshi T, Kinoshita H, Hirose T and Monden Y: Artificial lymphogenous metastatic model using orthotopic implantation of human lung cancer. Ann Thorac Surg. 69:1691–1695. 2000. View Article : Google Scholar : PubMed/NCBI
10	Fujino H, Kondo K, Ishikura H, et al: Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. Mol Cancer Ther. 9:1409–1416. 2005. View Article : Google Scholar
11	Kondo K, Fujino H, Miyoshi T, Ishikura H, Sakiyama S and Monden Y: Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drug effects. Oncol Rep. 5:991–999. 2004.
12	Fujino H, Kondo K, Miyoshi T, et al: Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues. Oncol Rep. 6:1709–1715. 2003.
13	Chen ZS and Tiwari AK: Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
14	Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance associated proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
15	Loe DW, Almquist KC, Deeley RG and Cole SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem. 271:9675–9682. 1996. View Article : Google Scholar : PubMed/NCBI
16	Tiwari AK, Sodani K, Dai CL, Ashby CR Jr and Chen ZS: Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 12:570–594. 2011. View Article : Google Scholar
17	Loe DW, Deeley RG and Cole SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58:5130–5136. 1998.PubMed/NCBI
18	Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B and Keri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta. 1587:318–325. 2002. View Article : Google Scholar : PubMed/NCBI
19	Nooter K, Westerman AM, Flens MJ, et al: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1:1301–1310. 1995.PubMed/NCBI
20	Nooter K, Brutel de la Riviere G, Klijn J, Stoter G and Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet. 349:1885–1886. 1997. View Article : Google Scholar : PubMed/NCBI
21	Deeley RG, Westlake C and Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 86:849–899. 2006. View Article : Google Scholar : PubMed/NCBI
22	Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 55:929–937. 1999.PubMed/NCBI
23	Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H and Sugiyama Y: Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther. 281:304–314. 1997.PubMed/NCBI
24	Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH and Schinkel AH: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 116:824–829. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sandusky GE, Mintze KS, Pratt SE and Dantzig AH: Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology. 41:65–74. 2002. View Article : Google Scholar : PubMed/NCBI
26	van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Muller M and Vellenga E: Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34⁺ peripheral blood cells. Clin Cancer Res. 4:1727–1736. 1998.PubMed/NCBI
27	Korita PV, Wakai T, Shirai Y, et al: Multidrug resistance associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 23:965–972. 2010.PubMed/NCBI
28	Nagahara N and Nishino T: Role of amino acid residues in the active site of rat liver mercaptopyruvate sulfurtransferase. cDNA cloning, overexpression, and site-directed mutagenesis. J Biol Chem. 271:27395–27401. 1996. View Article : Google Scholar : PubMed/NCBI
29	Ramasamy S, Singh S, Taniere P, Langman MJ and Eggo MC: Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation. Am J Physiol Gastrointest Liver Physiol. 291:G288–G296. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ooyama A, Takechi T, Toda E, et al: Gene expression analysis using human cancer xenografts to identify novel predictive marker. Cancer Sci. 97:510–522. 2006. View Article : Google Scholar : PubMed/NCBI
31	Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI
32	Golub TR: Genome-wide views of cancer. N Engl J Med. 8:601–602. 2001. View Article : Google Scholar
33	Mayer F, Hartmann JT, von Pawel J, et al: A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. Ann Oncol. 5:755–759. 2002. View Article : Google Scholar
34	Nukatsuka M, Fujioka A, Nakagawa F, et al: Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol. 25:1531–1536. 2004.PubMed/NCBI
35	Kiyohara C and Yoshimasu K: Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 4:59–71. 2007. View Article : Google Scholar : PubMed/NCBI
36	Ott K, Rachakonda PS, Panzram B, et al: DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 18:2688–2698. 2011. View Article : Google Scholar : PubMed/NCBI
37	Yin M, Yan J, Martinez-Balibrea E, et al: ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and metaanalysis. Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
38	Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI